A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A STUDY OF THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF DRM01B TOPICAL GEL IN HEALTHY VOLUNTEERS AND SUBJECTS WITH ACNE VULGARIS

Intervention/treatment:
DRM01B
Medical condition:
ACNE
Protocol code:
DRM01B-ACN01
Control number:
166170
Status:
Closed
Approved:
July 31, 2013
Date Completed:
Trial phase:
Phase 1, Phase 2
For more information:
ClinicalTrials.gov - NCT01936324
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: Yes

Contacts and locations

Contact
Name
Chief Medical Officer
Organization
Eli Lilly and Company
Phone:
800-545-5979
Sponsor
DERMIRA INCORPORATED

Locations

British Columbia

Centre de Recherche Dermetologique du Quebec Metropolitain (CRDQ)
Québec, British Columbia, G1V 4X7
Guildford Dermatology Specialist Inc
Surrey, British Columbia, V3R 6A7

Ontario

Institute of Cosmetic & Laser Surgery
Oakville, Ontario, L6J 7W5
K. Papp Clinical Research Inc.
Waterloo, Ontario, N2J 1C4
Lynderm Research Inc
Markham, Ontario, L3P1A8
Research Toronto
Toronto, Ontario, M5S 3B4
Skin Centre for Dermatology
Peterborough, Ontario, K9J 1Z2
The Centre for Dermatology
Richmond Hill, Ontario, L4B 1A5
Ultranova Skincare
Barrie, Ontario, L4M 6L2
Windsor Clinical Research, Inc.
Windsor, Ontario, N8W 5W7

Quebec

Innovaderm Research, Inc
Montreal, Quebec, H2K 4L5
Siena Medical Research
Montreal, Quebec, H3Z 2S6

Results

See the results from the trial NCT01936324. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?